Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new...

12

Transcript of Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new...

Page 1: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 2: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 3: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 4: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 5: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 6: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 7: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 8: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 9: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 10: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 11: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves
Page 12: Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents ? minimum inhibitory concentration versus time-kill curves

Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

Anti-infective potential of marine invertebrates and seaweeds from the Brazilian coast

Anti-infective potential of marine invertebrates and seaweeds from the Brazilian coast

Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats

Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats

Role of pharmacodynamic, pharmacogenetic and pharmacogenomic biomarkers of cancer chemotherapy with antifolates

Role of pharmacodynamic, pharmacogenetic and pharmacogenomic biomarkers of cancer chemotherapy with antifolates

Physiologically Based Pharmacokinetic and Toxicokinetic Models

Physiologically Based Pharmacokinetic and Toxicokinetic Models

A PHYSIOLOGICALLY BASED PHARMACOKINETIC

A PHYSIOLOGICALLY BASED PHARMACOKINETIC

Stability and performance of a population pharmacokinetic model 486 #{149} J ClinPharmacol Stability and Performance of a Population Pharmacokinetic Model

Stability and performance of a population pharmacokinetic model 486 #{149} J ClinPharmacol Stability and Performance of a Population Pharmacokinetic Model

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

Accounting for pharmacokinetic differences in dual-tracer receptor density imaging

Accounting for pharmacokinetic differences in dual-tracer receptor density imaging

Novel Anti-Infective Compounds from Marine Bacteria

Novel Anti-Infective Compounds from Marine Bacteria

Anti-Infective Treatment and Resistance Is Rarely Problematic ...

Anti-Infective Treatment and Resistance Is Rarely Problematic ...

Using Pharmacokinetic modeling to enhance Mn risk assessment

Using Pharmacokinetic modeling to enhance Mn risk assessment

Diagnosis, treatment and prevention of infective endocarditis

Diagnosis, treatment and prevention of infective endocarditis

AZELAIC ACID: PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES AND ITS THERAPEUTIC ROLE IN HYPERPIGMENTARY DISORDERS AND ACNE

AZELAIC ACID: PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES AND ITS THERAPEUTIC ROLE IN HYPERPIGMENTARY DISORDERS AND ACNE

The pharmacokinetic interaction between cyclosporine and ...

The pharmacokinetic interaction between cyclosporine and ...

Polymorphic drug oxidation: pharmacokinetic basis ... - NCBI

Polymorphic drug oxidation: pharmacokinetic basis ... - NCBI

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Pharmacokinetic Interaction between Atorvastatin and Omega ...

Pharmacokinetic Interaction between Atorvastatin and Omega ...

MOLECULAR DOCKING AND PHARMACOKINETIC ...

MOLECULAR DOCKING AND PHARMACOKINETIC ...

Pharmacokinetic and Pharmacodynamic Comparison of Once Daily Efavirenz (400mg Versus 600mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

Pharmacokinetic and Pharmacodynamic Comparison of Once Daily Efavirenz (400mg Versus 600mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study